-
Mashup Score: 0
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Marketing Authorisation Application (MAA) to the Eur
Source: www.businesswire.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma - Leukemia - 2 year(s) ago
Despite the recent progress, multiple myeloma (MM) is still essentially incurable and there is a need for additional effective treatments with good tolerability. RO7297089 is a novel bispecific BCMA/CD16A-directed innate cell engager (ICE®) designed to induce BCMA+ MM cell lysis through high affinity binding of CD16A and retargeting of NK cell cytotoxicity and macrophage phagocytosis. Unlike…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
A BCMA/CD16A #bispecific innate cell engager for the treatment of multiple #myeloma #mmsm https://t.co/79T20r2fIt
-
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma #mmsm https://t.co/py38ToCpS5
-
-
Mashup Score: 2Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts | Immunotherapy - 3 year(s) ago
Colorectal cancer (CRC) is identified as a life-threatening malignancy. Despite several efforts and proceedings available for CRC therapy, it is still a health concern. Among a vast array of novel therapeutic procedures, employing bispecific antibodies (BsAbs) is currently considered to be a promising approach for cancer therapy. BsAbs, as a large family of molecules designed to realize two…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A comphrensive review of the emerging usages for novel #bispecific antibodies in #colorectal cancer clinical trials has been detailed by researchers from several Iranian universities in our November issue 📚 - https://t.co/Dq8fkWilI3 #CRC #BsAbs https://t.co/0notkvOzle
-
-
Mashup Score: 1Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells - 3 year(s) ago
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent bispecific antibody designed to suppress the PD-1 pathway and provide modulated CTLA4 inhibition favoring enhanced blockade on PD-1+ activated T…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the May issue: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. @SJDovedi @AstraZeneca #immunotherapy https://t.co/gPQgvcp2ub https://t.co/iptKmvbVTB
-
-
Mashup Score: 0Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients #Lymphoma #LargeBcell #Diffuse #Tafasitamab #CARTcell #Antibodies #Bispecific #DLBCL https://t.co/6AFKUCnALa https://t.co/gfvvC2w9qW
-
-
Mashup Score: 0Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells - 3 year(s) ago
The clinical benefit of PD-1 blockade can be improved by combination with CTLA-4 inhibition but is commensurate with significant irAEs sub-optimally limiting the doses of anti-CTLA-4 mAb that can be used. MEDI5752 is a monovalent bispecific antibody designed to suppress the PD-1 pathway and provide modulated CTLA-4 inhibition favouring enhanced blockade on PD-1+ activated T cells. We show that…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. @SJDovedi @AstraZeneca #immunotherapy https://t.co/uqcxVPmSLp https://t.co/Cd2I9Y0ZqN
-
-
Mashup Score: 1Preliminary results of phase I trials on safety and tolerability of bispecific antibodies and BiTEs for RRMM - 3 year(s) ago
At the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held in December 2020, data on safety and efficacy were presented for four novel treatments, which have been summarized in this article.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Safety and tolerability of #bispecific antibodies reported at #ASH20 in relapsed/refractory multiple #myeloma patients. Preliminary results from phase I trials https://t.co/ciyplx5IWo #mmsm
-
-
Mashup Score: 2Fast track designation and phase II trial initiation with elranatamab, a BCMA/CD3 bispecific antibody - 3 year(s) ago
The first patient with relapsed/refractory multiple myeloma (MM) has been given a dose of elranatamab, a B-cell maturation antigen (BCMA) CD3 bispecific antibody in the phase II MagnetisMM-3 trial.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Elranatamab, a BCMA/CD3 #bispecific antibody, receives fast track designation from the @FDAOncology, and the first patient is dosed in a phase II study designed for triple-refractory multiple https://t.co/RQVC3MfpQS #myeloma #mmsm https://t.co/Fi4gXkESji
-
-
Mashup Score: 0Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells - 3 year(s) ago
The clinical benefit of PD-1 blockade can be improved by combination with CTLA-4 inhibition but is commensurate with significant irAEs sub-optimally limiting the doses of anti-CTLA-4 mAb that can be used. MEDI5752 is a monovalent bispecific antibody designed to suppress the PD-1 pathway and provide modulated CTLA-4 inhibition favouring enhanced blockade on PD-1+ activated T cells. We show that…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Just published #OnlineFirst: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. @SJDovedi @AstraZeneca #immunotherapy https://t.co/V2cxXmHz7l https://t.co/wRPDrYdhqv
-
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of #Bispecific Antibody Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple #Myeloma #mmsm https://t.co/86d1CHHj9F